Lucid Diagnostics Q3 2026 Earnings Date & Estimates

Lucid Diagnostics (NASDAQ:LUCD) is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer at an earlier, more treatable stage. The company is a subsidiary of PAVmed Inc. and develops diagnostic products intended to help identify patients at risk for esophageal adenocarcinoma, a cancer associated with Barrett’s esophagus and chronic gastroesophageal reflux disease.

Lucid’s primary products are EsoGuard, a laboratory-developed DNA test, and EsoCheck, a noninvasive, swallowable balloon device used to collect cells from the esophagus. Together, the products are designed to support screening of patients with chronic reflux or other risk factors who may not otherwise undergo traditional endoscopic evaluation. Testing is performed through Lucid’s laboratory operations in the United States.

The company was established to commercialize technologies developed for earlier detection of esophageal disease and has focused its activities primarily on the U.S. market. Lucid Diagnostics is headquartered in New York and operates as part of the PAVmed group of medical technology companies.